Intellectual property and the valuation of biotechnology
The role of intellectual property (IP) as an important value determinant is widely recognized. This article tries to quantify the role of IP in companies valuation by comparing a sample of biotechnology companies (46 companies included in the Genetic Engineering News Index:GEN-Dex) to the companies included in the Dow Jones Index. Conventional wisdom suggests that the biotechnology sector derives more significant portion of its value from IP. The article proposes a new measure for the significance of IP in the determination of value, which is named the IP Intensity (IPI). Comparison of the distribution of IPI in the two samples demonstrates that this measure is a useful tool for the analysis of value determination.
When requesting a correction, please mention this item's handle: RePEc:wpa:wuwpfi:9709002. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (EconWPA)
If references are entirely missing, you can add them using this form.